[6]
The NOA was made in relation to Novopharm's Abbreviated New Drug Submission ("ANDS") for its proposed lansoprazole 15 mg and 30 mg delayed release capsules. The NOA contains allegations of non-infringement with respect to Canadian Patent Nos. 1,312,548 and 2,009,741.